Also known as Tagrisso.
Approval allows FoundationOne CDx to detect BRAF V600 alterations and BRAF fusion genes to guide tovorafenib treatment in glioma and expands companion indications to nine cancer types.
FDA approves RYBREVANT FASPRO™ for EGFR-mutated NSCLC, offering faster, subcutaneous administration with fewer side effects compared to IV delivery.
